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Abstract
Background and Purpose—Among children with arterial ischemic stroke (AIS), those with 
arteriopathy have the highest recurrence risk. We hypothesized that arteriopathy progression is an 
inflammatory process, and that inflammatory biomarkers would predict recurrent AIS.
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Methods—In an international study of childhood AIS, we selected cases classified into one of 
the three most common childhood AIS etiologies: definite arteriopathic (N=103), cardioembolic 
(N=55), or idiopathic (N=78). We measured serum concentrations of high sensitivity C-reactive 
protein (hsCRP), serum amyloid A (SAA), myeloperoxidase (MPO), and tumor necrosis factor 
alpha (TNF-α). We used linear regression to compare analyte concentrations across the subtypes, 
and Cox proportional hazards models to determine predictors of recurrent AIS.
Results—Median age at index stroke was 8.2 years (IQR 3.6, 14.3); serum samples were 
collected at median 5.5 days post-stroke (IQR 3, 10 days). In adjusted models (including age, 
infarct volume, and time to sample collection) with idiopathic as the reference, the cardioembolic 
(but not arteriopathic) group had higher concentrations of hsCRP and MPO, while both 
cardioembolic and arteriopathic groups had higher SAA. In the arteriopathic (but not 
cardioembolic) group, higher hsCRP and SAA predicted recurrent AIS. Children with progressive 
arteriopathies on follow-up imaging had higher recurrence rates, and a trend towards higher 
hsCRP and SAA, compared to children with stable or improved arteriopathies.
Conclusion—Among children with AIS, specific inflammatory biomarkers correlate with 
etiology and—in the arteriopathy group—risk of stroke recurrence. Interventions targeting 
inflammation should be considered for pediatric secondary stroke prevention trials.
Keywords
ischemic stroke; pediatric stroke; inflammatory biomarkers; C-reactive protein
INTRODUCTION
Although childhood arterial ischemic stroke (AIS) is a heterogeneous disorder, most cases 
fall into one of three broad etiologic categories: arteriopathic, cardioembolic, and 
idiopathic.1 Presence of an arteriopathy (cervical or cerebral) confers an increased risk of 
recurrent AIS.2–5 In the prospective, multicenter “Vascular effects of Infection in Pediatric 
Stroke” (VIPS) study, children with arteriopathic stroke had a 21% (95% CI, 14%–29%) 
chance of recurrence within 1 year, compared to 8% (95% CI 3%–18%) with cardioembolic 
and 5% (95% CI, 2%–12%) with idiopathic stroke.2 Childhood arteriopathies are themselves 
heterogeneous and poorly understood,6 yet mounting evidence suggests that infection and 
inflammation play a role in their pathogenesis. The VIPS study, and others, provide evidence 
that acute infection, such as the common cold or herpesviruses, act as triggers for childhood 
AIS.7–10 Arterial wall imaging studies detecting enhancement in the wall of affected vessels 
in childhood arteriopathies may suggest an acute inflammatory process.11, 12 Children 
whose arteriopathies progress after their index stroke have the highest risk of recurrent 
AIS.13, 14 We hypothesized that arteriopathy progression is an inflammatory process, and 
that markers of inflammation would predict recurrent AIS in childhood. To explore this 
hypothesis, we measured serum levels of four soluble immune mediators in children with 
AIS enrolled in the VIPS study: hsCRP, SAA, MPO, and TNF-α. These four analytes were 
selected because of their published associations with adult stroke and vascular disease.15, 16
Fullerton et al. Page 2
Stroke. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
METHODS
Study subjects and sample collection
The VIPS study prospectively enrolled and centrally confirmed 355 children (29 days 
through 19 years) with AIS at 37 international sites from 1/2010–3/2014. Details of our 
methods for enrollment, case confirmation, data collection, classification of etiology, 
parental interview, sample collection, and ascertainment and confirmation of recurrent AIS 
are published.2, 6–8, 17 In brief, a team of pediatric stroke neurologists and neuroradiologists 
confirmed cases after central review of imaging and clinical features. A single 
neuroradiologist (M.W.) estimated infarct volume using the ABC/2 method.18 A central 
team similarly reviewed all clinically-obtained cerebrovascular imaging and clinical data to 
classify cases as “definite,” “possible,” or “no arteriopathy”; “no arteriopathy” cases were 
further classified into cardioembolic, other specific etiology, or idiopathic.6 When 
arteriopathic cases had follow-up imaging, the team classified evolution as “stable”, 
“improves or resolves”, “progresses”, or “progresses then improves or resolves”. For 
analysis, these categories were dichotomized as “stable/improving/resolved” vs. 
“progression” (regardless of subsequent improvement). The study protocol included a 
minimum follow-up of 1 year. Recurrent AIS, defined as “a new acute infarction in an 
arterial territory with corresponding new or worsening clinical signs and symptoms,” was 
centrally confirmed.2
Laboratory methods
Blood samples were collected locally as soon as possible after enrollment, up to 21 days 
post-stroke. They were centrifuged at 3000 rpm for 10 minutes, with serum samples 
immediately separated, aliquoted and stored in 1.2 mL cryovials at −70°C. Samples were 
then shipped on dry ice to the Center for Advanced Laboratory Medicine (CALM) at 
Columbia University, and were run in batches by technicians blind to clinical status. HsCRP 
and SAA concentrations were measured using a clinically-validated BNII nephelometer 
(Siemens Dade Behring, Deerfield, IL). TNF-α (Invitrogen, Camarillo, CA) and MPO 
(R&D Systems Inc., Minneapolis, MN) concentrations were measured using enzyme-linked 
immunosorbent assays following the manufacturer’s instructions. Assay performance was 
within the manufacturer’s specifications.
Data analysis
Analysis focused on cases that could be classified with a high degree of certainty into one of 
the three most common etiologic groups: arteriopathic, cardioembolic, or idiopathic (Figure 
1). From the overall VIPS cohort of 355 children, we excluded those with “possible” 
arteriopathy (likely a mixture of etiologies),6 or other specific etiologies not falling into the 
three major categories of interest. We also excluded cases with major infections (sepsis, 
meningitis/encephalitis, endocarditis) which would impact serum concentrations of 
inflammatory biomarkers. We compared analyte concentration levels in the remaining 
children. Kruskal-Wallis tests were used to make unadjusted comparisons of each analyte 
individually across the three etiologic groups; linear regression models examined the 
associations between individual analytes and stroke etiology while adjusting for potential 
confounders (age, sex, infarct volume, time from stroke to blood sampling, seizures at 
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presentation, and clinical infection in the week preceding stroke). For regression analyses, 
analyte concentration levels were used as outcomes and log-transformed to reduce the 
skewness of residuals; our primary predictor was etiology group with idiopathic as a 
reference.
To assess variables related to risk of recurrent AIS, we used survival analysis techniques as 
previously described; the outcome was defined as the time from index AIS to first recurrent 
AIS and cases were censored at death or loss to follow-up.2 To determine whether analyte 
concentrations correlated with recurrent AIS, we created Cox proportional hazards models. 
Each analyte was analyzed individually to determine its potential association with 
recurrence. Analyte concentrations were log-base 2 transformed to yield relative hazards 
associated with a doubling of concentration. We adjusted for stroke etiology, as well as those 
variables included in the linear regression models above. To investigate potential interactions 
by stroke etiology, we included an interaction term in our Cox models, and performed 
analyses stratified by subtype. Only the arteriopathic and cardioembolic subgroups were 
assessed in these analyses because of the paucity of outcomes (recurrence) in the idiopathic 
group. Among the subgroup of children with arteriopathic stroke and follow-up vascular 
imaging, we analyzed arteriopathy progression as a dichotomous predictor of recurrent AIS; 
to maintain consistency across models, we adjusted for the potential confounders described 
above.
Our α-level was set at 0.05. All analyses were conducted using Stata v12 (Stata Corp., 
College Station, TX).
RESULTS
The present analysis included 236 children with AIS whose etiology was classified into one 
of three major groups (Figure 1): idiopathic (n=78), arteriopathic (n=103), or cardioembolic 
(n=55). Median age at stroke ictus was 8.2 years overall (interquartile range [IQR], 3.6, 
14.3), and was higher in the idiopathic group (11.8) than the arteriopathic (7.5) or 
cardioembolic (5.1) groups (p=0.07); 134 (57%) were boys. The median time from stroke 
ictus to collection of the serum sample was 5.5 days (IQR 3, 10 days); we included four 
samples collected beyond the 21 day window (Figure 2). Concentrations of hsCRP and SAA 
correlated with infarct size, but MPO and TNF-α did not (Supplemental Figure I).
Inflammatory markers and stroke etiology
In our unadjusted analyses, there were significant differences in all analyte concentrations 
across all three etiologic groups (Table 1). In the adjusted models, compared to children with 
idiopathic stroke, children with cardioembolic stroke had higher concentrations of three 
analytes (hsCRP, SAA, and MPO), while those with arteriopathic stroke had higher levels of 
only one analyte, SAA. (Adjustment for seizures and infection in the preceding week had 
minimal impact on the models; data not shown).
Inflammatory markers and recurrent AIS
The 236 children were followed for a median of 23 months (range 7 days to 60 months) 
following index stroke. During follow-up, 31 children had a recurrent AIS: 24 (23%) of 103 
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in the arteriopathic group, 5 (9%) of 55 in the cardioembolic group, and 2 (3%) of 78 in the 
idiopathic group. Higher concentrations of two analytes—hsCRP and SAA—were 
associated with an increased hazard of recurrent AIS in children with arteriopathic, but not 
cardioembolic stroke (Table 2; test for interaction, p=0.87 for hsCRP and p=0.31 for SAA). 
The effect size was similar for both analytes: doubling of their concentrations increased the 
hazard of recurrence after arteriopathic AIS by 16% (Table 2). Cumulative recurrence risk 
after arteriopathic AIS, stratified by analyte concentration above versus below the median, is 
shown in Figure 3 (A&B). The two markers were highly collinear (r=0.82, p<0.0001), so 
could not be included in the same Cox model.
Arteriopathy progression and recurrent AIS
Among the 103 children with arteriopathic stroke, 62 (60%) had centrally-reviewed follow-
up vascular imaging (Supplemental Table I). The median time from index stroke to final 
vascular imaging included in these analyses was 5 months (IQR 1, 12 months). The 
arteriopathy was classified as progressive in 30 (48%) and nonprogressive (stable or 
improved) in 32 (52%). In an analysis of these 62 children, arteriopathy progression 
increased the hazard of recurrent AIS three-fold (adjusted HR 3.1, 95% CI 1.1, 8.7, 
p=0.036). Among children with progressive arteriopathy, the 1-year cumulative risk of 
recurrence was 46% (95% CI, 25, 84%) compared to 25 % (95% CI, 12, 52%) among those 
with nonprogressive arteriopathy (Figure 3C).
Inflammatory markers and arteriopathy progression
The median hsCRP concentration was 1.62 mg/L (IQR 0.46, 7.28) in the progressive group 
(N=28), compared to 0.87 mg/L (IQR 0.16, 4.13) in the nonprogressive group (N=31; 
unadjusted p=0.20, Wilcoxon rank-sum test). The median SAA concentration was 14.2 
mg/L (IQR 1.7, 59) in the progressive group (N=29), compared to 3.9 mg/L (IQR 1.4, 13.3) 
in the nonprogressive group (N=29; unadjusted p=0.067, Wilcoxon rank-sum test). Adjusted 
linear regression models did not find significant associations between arteriopathy 
progression and log-transformed concentrations of hsCRP (p=0.283) and SAA (p=0.089).
DISCUSSION
In a large, international study of childhood AIS, serum concentrations of three of four 
measured inflammatory biomarkers differed by stroke etiology, even after adjusting for 
potential confounders. Two of these—the acute phase reactants CRP and SAA—predicted 
risk of recurrent AIS among children with arteriopathic stroke, the subgroup at highest risk 
for recurrence. Children with progressive arteriopathies had the highest recurrence risk, and 
a trend towards higher hsCRP and SAA concentrations. These findings have important 
implications for the development of new strategies for secondary stroke prevention in 
childhood.
Two prior studies of childhood AIS, the Swiss Neuropediatric Stroke Registry Study Group 
(N=12 cases, N=7 controls) and a single-center US study (N=50 cases), measured serum 
levels of inflammatory biomarkers; both found elevated hsCRP, while other markers, 
including TNFα, were not significantly different.19, 20 Elevations in these serum markers 
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measured post-stroke could reflect, in part, downstream effects of the infarct itself related to 
tissue destruction and breakdown of the blood brain barrier. Because we could collect only 
post-stroke serum samples, we adjusted our analyses for infarct size, seizures, and timing of 
the serum sample relative to the stroke. Although residual confounders may exist, several 
pieces of evidence indicate that these markers also reflect upstream mechanisms underlying 
the stroke pathogenesis. First, adult studies similarly found that serum levels of soluble 
immune mediators (TNFα, IL-6, and IL-1β) correlate with stroke etiology.21, 22 Second, we 
observed large variations in biomarker concentrations even amongst children with very low 
volume infarcts that should have had minimal systemic effects (Supplemental Figure I). 
Third, the observed associations between biomarkers and recurrence risk in the arteriopathic 
group suggest that inflammation may be contributing to the pathogenesis of subsequent 
strokes.
Systemic inflammation could play a complex role in AIS pathogenesis. Circulating immune 
mediators can activate the coagulation system, promoting thrombosis, and can injure arterial 
and cardiac endothelium.23 The different patterns of immune activation we observed across 
our three etiologic subgroups suggest that inflammation may play different roles in different 
childhood stroke etiologies. We speculate that systemic inflammation interacts with other 
pediatric stroke risk factors, like congenital heart disease and trauma. In a child with a 
structurally abnormal heart, inflammation might trigger intracardiac thrombus formation and 
cardioembolic stroke. Inflammation might make the cervical arteries more vulnerable to 
dissection; exposure to trauma after arteries have been “primed” by inflammation could 
trigger arteriopathic stroke.
The link between inflammation, arteriopathy and stroke recurrence in childhood has 
previously been postulated, but never directly studied.12, 20 Arterial wall imaging studies 
suggest that some childhood arteriopathies may be inflammatory in nature.11, 12 Other 
studies have reported a correlation between arteriopathy progression and increased risk of 
recurrence.13, 14 We confirmed that children with progressive arteriopathy have the highest 
risk of recurrent AIS: almost half had a recurrence within one year, most within the first 30 
days, compared to 12% of the VIPS cohort overall.2 We demonstrated for the first time that 
higher levels of two inflammatory biomarkers (hsCRP and SAA) correlate with higher 
recurrence risk after arteriopathic stroke, particularly in the first 60 days (Figure 3, A&B). 
We observed a trend towards a correlation between those markers and arteriopathy 
progression (but were likely underpowered because only a subset of cases had follow-up 
vascular imaging). Although our observational data can demonstrate only correlation, and 
not causation, we hypothesize that arteriopathy progression results from on-going 
inflammation of the affected arteries. This hypothesis could be tested in a randomized 
controlled trial of anti-inflammatory therapy for secondary stroke prevention in childhood. 
Such a trial design, however, would need to consider the role of infection and other factors 
in pathogenesis, and the concern for immunosuppression in the setting of acute infection.
The four specific immune mediators we measured provide a window into a complex immune 
response. SAA concentrations were elevated in both our arteriopathic and cardioembolic 
cases, and correlated with recurrence in the arteriopathic group. SAA is not only a 
biomarker, but a participant in the innate immune response. It promotes adhesion, migration, 
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and infiltration of lymphocytes and monocytes; regulates production of cytokines by 
inflammatory cells; and increases generation of extracellular matrix metalloproteinases.24, 25 
Through these effects, SAA plausibly participates in damage to arterial or cardiac 
endothelium that may be relevant to childhood stroke. SAA is elevated in adults with both 
Takayasu arteritis and giant cell arteritis, and correlates with disease activity of 
inflammatory arteriopathies.26, 27
HsCRP was significantly elevated only in our cardioembolic cases, although there was a 
trend towards higher levels in arteriopathic cases. Levels also correlated with recurrence risk 
in the arteriopathic group. CRP is an acute phase reactant used clinically as a non-specific 
marker of inflammation; it predicts a broad variety of cardiovascular and non-cardiovascular 
causes of morbidity and mortality, including adult AIS, prognosis after stroke, and 
atherosclerosis.28–30 Mounting evidence indicates that CRP, like SAA, is not only a 
biomarker but a participant in the innate immune response.31, 32 The aforementioned Swiss 
study reported higher median hsCRP levels in their 12 cases of childhood AIS (median 5.9 
µg/ml, range 0.13, 98) than seven age-matched control children (median 0.12 µg/ml; range 
0.003, 4.1; p=0.007).19 The single-center U.S. study of childhood AIS reported similar 
median CRP concentrations for cardioembolic (N=11) and arteriopathic (N=26) subtypes, 
compared to our study, but was underpowered to detect a significant difference.20 
Regardless, the non-specificity of CRP may limit its utility in distinguishing among 
mechanisms of stroke subtype, while it may still be useful as a marker of recurrent stroke 
risk among children with arteriopathic stroke.
MPO was elevated in our cardiac cases, and did not appear important in our arteriopathic 
cases. MPO levels correlate with active coronary artery disease (CAD), predicting risk of 
myocardial infarction.16 Atherosclerosis and CAD are unlikely to be contributors to stroke 
risk in children, but other childhood cardiac disorders are associated with stroke risk and 
could explain some of the association with MPO. TNFα, which has been associated with 
cardioembolic stroke in adults,21, 22 did not correlate with either stroke etiology or 
recurrence in our pediatric study, nor was it elevated in the cases of childhood AIS in the 
Swiss study.19 TNFα is a less stable marker in stored specimens, however, and associations 
may thus be limited by measurement error.
In addition to the limitation of having only post-stroke serum samples available for analysis, 
our study has a number of other limitations. Although VIPS is the largest-ever prospective 
study of childhood AIS, some of our analyses may have been underpowered to detect actual 
differences between groups. Because we had only clinically obtained imaging, our analyses 
of arteriopathy progression were likely biased as children are more likely to get follow-up 
imaging if they have a recurrent stroke. Hence, our estimates of stroke recurrence among 
children with arteriopathy progression and non-progression were likely overestimates. For 
feasibility of enrollment, our blood samples were collected alongside clinical phlebotomy 
over a three-week window after the stroke; late samples may have been less likely to reflect 
pre-stroke inflammatory processes. Published pediatric normative values for most of our 
analytes are not available, and we did not have serum samples from healthy control children. 
The VIPS study collected blood samples only from trauma controls (for antibody titers), and 
the trauma would likely have affected the inflammatory biomarker concentrations. Lastly, 
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we measured only four biomarkers; since our study began, more immune mediators have 
been linked to stroke and vascular injury.23 The renewal of the VIPS study proposes to 
address many of these limitations by collecting serum samples in a shorter time window (72 
hours post-stroke), using multiplex technology to analyze a large number of inflammatory 
markers, and collecting serum samples from well children undergoing elective procedures.
CONCLUSIONS
Different inflammatory responses may underlie the heterogeneity in childhood stroke 
pathogenesis and recurrent stroke risk. Because children with progressive arteriopathies have 
the highest risk of recurrent AIS, a better understanding of the inflammatory processes 
underlying their arteriopathies will guide the development of secondary stroke prevention 
strategies.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Flow diagram showing the 236 VIPS cases included in the current analysis.
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Figure 2. 
Histogram demonstrating time in days from stroke ictus to serum sample collection (n=236).
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Figure 3. 
Nelson-Aalen plots demonstrating cumulative incidence of recurrent arterial ischemic stroke 
(AIS) after index arteriopathic AIS. Panels A and B show recurrence for children with 
definite arteriopathy stratified by hsCRP (panel A; N=98) and SAA (panel B; N=97) 
concentrations that are above versus below the median concentration. Panel C shows 
recurrence among 62 children with definite arteriopathy and follow-up vascular imaging, 
stratified by arteriopathy progression.
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